Lifecore Biomedical (LFCR) to Release Quarterly Earnings on Monday

Lifecore Biomedical (NASDAQ:LFCR) is projected to issue its Q4 2025 quarterly earnings data before the market opens on Monday, August 25th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $35.36 million for the quarter. Lifecore Biomedical has set its FY 2026 guidance at EPS.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $36.44 million for the quarter, compared to analysts’ expectations of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Trading Down 0.7%

LFCR opened at $7.37 on Monday. The firm has a market capitalization of $275.71 million, a P/E ratio of -5.63 and a beta of 0.65. The firm’s 50 day moving average is $7.53 and its 200-day moving average is $6.76. Lifecore Biomedical has a 52-week low of $3.68 and a 52-week high of $8.85. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LFCR. Wall Street Zen raised shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday. William Blair began coverage on shares of Lifecore Biomedical in a research report on Wednesday, May 21st. They set an “outperform” rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Insider Buying and Selling at Lifecore Biomedical

In other news, major shareholder Aron R. English sold 150,419 shares of the firm’s stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the completion of the sale, the insider owned 264,180 shares of the company’s stock, valued at approximately $1,880,961.60. This trade represents a 36.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 1,386,060 shares of company stock worth $9,126,684 over the last three months. 32.20% of the stock is currently owned by company insiders.

Institutional Trading of Lifecore Biomedical

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in Lifecore Biomedical by 3.3% in the second quarter. Geode Capital Management LLC now owns 775,493 shares of the company’s stock worth $6,299,000 after purchasing an additional 24,995 shares during the period. Invesco Ltd. acquired a new position in Lifecore Biomedical in the second quarter worth $3,081,000. Goldman Sachs Group Inc. boosted its holdings in Lifecore Biomedical by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company’s stock worth $620,000 after purchasing an additional 12,647 shares during the period. Rhumbline Advisers boosted its holdings in Lifecore Biomedical by 54.0% in the second quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock worth $309,000 after purchasing an additional 13,361 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after purchasing an additional 1,886 shares during the period. Institutional investors and hedge funds own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.